Bayer
In Brief This Week: Caris Life Sciences, Psomagen, Tempus, CareDx, HTG Molecular, Epigenomics, More
News items for the week of Nov 8, 2021.
Bayer, Veracyte to Identify Therapy-Resistant Thyroid Cancer Patients
Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.
Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer
The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.
FDA Approves Foundation Medicine CDx, Bayer's Vitrakvi for NTRK Patients
The test analyzes substitutions, insertion and deletion alterations, and copy number alterations in 324 genes, along with some genomic signatures in solid tumors.
ArcherDx, Bayer Partner on NGS-Based Companion Diagnostic Test Development
The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.
Apr 26, 2019
Apr 2, 2019
Oct 31, 2018
Nov 27, 2017
Jul 18, 2016
T2 Biosystems, Bayer Ink Hemostasis R&D Deal
May 17, 2016
Bayer Inks CRISPR Patent Licensing Agreement
May 16, 2014